SciELO - Scientific Electronic Library Online

 
vol.42 issue1The importance of assessing personality traits and disorders in clinical trials of major depressive disorderNeuroimaging adolescents with depression in a middle-income country: feasibility of an fMRI protocol and preliminary results author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Brazilian Journal of Psychiatry

Print version ISSN 1516-4446On-line version ISSN 1809-452X

Braz. J. Psychiatry vol.42 no.1 São Paulo Jan./Feb. 2020  Epub Feb 03, 2020

https://doi.org/10.1590/1516-4446-2019-0628 

EDITORIAL

Schneider’s first-rank symptoms and treatment outcome

1Departamento de Psiquiatria, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil


The diagnosis of schizophrenia and its differentiation from other disorders with psychotic symptoms has always been challenging in the field of psychiatry. Historically, the concept of schizophrenia spectrum disorder, as well as its symptoms and diagnostic criteria, were described by several authors in the 19th and 20th centuries, including Benedict-Augustin Morel, Emil Kraepelin, Paul Eugen Bleuler, and Kurt Schneider. Schneider’s conceptualization of first-rank symptoms (FRS) was a particularly important contribution to the diagnosis of schizophrenia.1

Schneider’s FRS were intended to differentiate schizophrenia reliably from other psychotic disorders. For this purpose, he qualitatively organized symptoms as first- or second-rank. Schneider’s description influenced the Research Diagnostic Criteria, ICD-10, DSM-III, and DSM-IV.2 Although FRS were excluded in the DSM-5 Criterion A for schizophrenia, they directly impacted diagnostic practice for decades.2,3

In a Cochrane review of diagnostic accuracy published in 2015, FRS had a sensitivity of 57% (50.4 to 63.3%) and a specificity of 81.4% (74 to 87.1%) for differentiation of schizophrenia from other psychiatric disorders.4 Despite several methodological issues in the included studies, this systematic review shows that assessment of FRS in patients could indeed help clinicians to diagnose schizophrenia.3

In this context, the present issue of the Brazilian Journal of Psychiatry includes an interesting article published by Malinowski et al. that relates psychopathology with treatment outcomes. Their study shows that the absence of specific FRS – arguing voices, voices commenting on one’s actions, and thought broadcasting – in patients having their first psychotic episode is related to remission after 2 months of risperidone therapy.5

It is worth mentioning that only 20% of studies included in the aforementioned Cochrane review of the diagnostic accuracy of FRS had been published after the year 2000; most were from the 1970s, 1980s, and 1990s.4 In this newly published paper, Malinowski et al. show that FRS remain currently relevant and could be useful in psychiatric diagnosis and as practical information to predict treatment outcomes of first psychotic episode.5 The availability of biomarkers to individualize and differentiate disorders is a possible and desirable objective for the future. While such new approaches are worthwhile, psychopathology studies remain fundamentally important to the practice of clinical psychiatry.

References

1. Lavretsky H. History of schizophrenia as a psychiatric disorder. In: Mueser KT, Jeste DV. Clinical handbook of schizophrenia. New York: Guilford; 2008. p. 3-13. [ Links ]

2. Kendler KS, Mishara A. The prehistory of Schneider's first-rank symptoms: texts from 1810 to 1932. Schizophr Bull. 2019;45:971-90. [ Links ]

3. Heinz A, Voss M, Lawrie SM, Mishara A, Bauer M, Gallinat J, et al. Shall we really say goodbye to first rank symptoms? Eur Psychiatry. 2016;37:8-13. [ Links ]

4. Soares-Weiser K, Maayan N, Bergman H, Davenport C, Kirkham AJ, Grabowski S, et al. First rank symptoms for schizophrenia. Cochrane Database Syst Rev. 2015;1:CD010653. [ Links ]

5. Malinowski FR, Tasso BC, Ortiz BB, Higuchi CH, Noto C, Belangero SI, et al. Schneider's first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis. Braz J Psychiatry. 2020;42:22-6. [ Links ]

Correspondence: Raffael Massuda, Departamento de Psiquiatria, UFPR, Rua Padre Camargo, 280, CEP 80060-240, Curitiba, PR, Brazil. E-mail: rfmassuda@ufpr.br

Disclosure The author reports no conflicts of interest.

How to cite this article: Massuda R. Schneider’s first-rank symptoms and treatment outcome. Braz J Psychiatry. 2020;42:5. http://dx.doi.org/10.1590/1516-4446-2019-0628

Creative Commons License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.